Lymphoma News and Research RSS Feed - Lymphoma News and Research

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists. [More]
Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942. [More]
LLS, Light The Night National Corporate Partner Teams make positive impact on patients' lives

LLS, Light The Night National Corporate Partner Teams make positive impact on patients' lives

The Leukemia & Lymphoma Society is working with thousands of national partners, sponsors and corporate teams to fund lifesaving research and support for people battling cancer through the Light The Night Walk. Together with LLS, the Light The Night National Corporate Partner Teams are raising awareness and making a positive impact on the lives of patients today, literally, by taking steps to save lives. [More]
Discovery could open up door for cancer research and treatment

Discovery could open up door for cancer research and treatment

Florida State University researchers have taken a big step forward in the fight against cancer with a discovery that could open up the door for new research and treatment options. [More]
Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP). [More]
Centenary Institute develops new therapeutic approach to prevent GVHD in blood cancer patients

Centenary Institute develops new therapeutic approach to prevent GVHD in blood cancer patients

Sydney’s Centenary Institute has developed a new therapeutic approach that could help to improve outcomes for patients undertaking treatment for blood cancer. [More]
Leukemia & Lymphoma Society to kick off 2015 Light The Night Walk campaign throughout Northern California

Leukemia & Lymphoma Society to kick off 2015 Light The Night Walk campaign throughout Northern California

The Leukemia & Lymphoma Society will be kicking off its 2015 Light The Night Walk campaign throughout Northern California with the Napa Valley Walk on September 26, 2015 at 5 p.m. PT at Veterans Memorial Park. [More]
PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand. [More]
STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand. [More]
Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax. [More]
Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain. [More]
NCI-MATCH phase II precision medicine trial opens through ECOG-ACRIN

NCI-MATCH phase II precision medicine trial opens through ECOG-ACRIN

The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) phase II precision medicine trial, known to doctors as trial EAY131, is open through the ECOG-ACRIN Cancer Research Group. [More]
Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

Researchers at Sydney’s Centenary Institute have taken the lead on a promising new class of drugs that may prove to be highly effective for the treatment of certain cases of melanoma. [More]
Organ transplant recipients more likely to develop melanoma

Organ transplant recipients more likely to develop melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and three times more likely to die of the dangerous skin cancer, suggests new research led by a Johns Hopkins Bloomberg School of Public Health student. [More]
Researchers help explain how malaria infection increases children's risk of developing Burkitt's lymphoma

Researchers help explain how malaria infection increases children's risk of developing Burkitt's lymphoma

In equatorial Africa, a region of the globe known as the "lymphoma belt," children are ten times more likely than in other parts of the world to develop Burkitt's lymphoma, a highly aggressive blood cancer that can be fatal if left untreated. That area is also plagued by high rates of malaria, and scientists have spent the last 50 years trying to understand how the two diseases are connected. [More]
Newly developed big data technique may have significant impact on health care

Newly developed big data technique may have significant impact on health care

Rice University scientists have developed a big data technique that could have a significant impact on health care. The Rice lab of bioengineer Amina Qutub designed an algorithm called "progeny clustering" that is being used in a hospital study to identify which treatments should be given to children with leukemia. [More]
UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico. [More]
AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis. [More]
Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

Barbara Ann Karmanos Cancer Institute, Wayne State University participate in NCI MATCH Trial

The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead academic centers participating in the National Cancer Institute's (NCI) MATCH (Molecular Analysis for Therapy Choice) Trial in the United States, set to begin in the next few weeks. [More]
Advertisement